Patents Examined by Brett Nelson
-
Patent number: 6046309Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: April 4, 2000Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 6042836Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: GrantFiled: August 13, 1998Date of Patent: March 28, 2000Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Patent number: 6040145Abstract: A method for stimulating proliferation of T-cells containing cytoplasmic post-prolyl dipeptidase activity; the method, in one aspect, involves contacting the T-cells with an organic compound at a concentration below 10.sup.-8 M, wherein the compound is characterized in that: (a) it is capable of crossing the membrane of T-cells to enter the cytoplasm, (b) it binds to the dipeptidase activity at a concentration of below 10.sup.-8 M, and thus (c) stimulates proliferation of the T-cells at that concentration.Type: GrantFiled: May 7, 1997Date of Patent: March 21, 2000Assignee: Tufts UniversityInventors: Brigitte T. Huber, Tracy Schmitz, Robert Underwood
-
Patent number: 6028118Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumoral, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being separated in a solid fraction (SOLID EXTRACT) and a liquid fraction which was further fractionated to obtain a LIQUID EXTRACT having molecules of a molecular weight comprised between 0 to 500 kDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components.Type: GrantFiled: August 8, 1996Date of Patent: February 22, 2000Assignee: Les Laboratoires Aeterna Inc.Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus
-
Patent number: 6025149Abstract: This invention represents a significant advance in prenatal diagnosis by providing urinary screening to detect fetal aneuploidies. Herein disclosed are methods for prenatally assessing risks of a pregnancy being affected by Down syndrome and other aneuploidies by testing maternal urine samples for levels of .beta.-core-hCG. Levels of maternal urinary .beta.-core-hCG above normal indicate a risk that the pregnancy is affected with Down syndrome, and in general risks of other fetal aneuploidies are indicated by either lower than normal or higher than normal maternal urinary .beta.-core-hCG levels. Assessments can be made based on urinary .beta.-core-hCG levels alone or in conjunction with levels of other urinary and/or serum markers, ultrasound parameters and other factors, such as, maternal age.Type: GrantFiled: July 3, 1996Date of Patent: February 15, 2000Assignee: Yale UniversityInventors: Howard S. Cuckle, Raymond K. Iles, Timothy Chard
-
Patent number: 6025169Abstract: The present invention relates to a method for controlling carbon source concentration in the aerobic cultivation of a microorganism. The substrate carbon source remains at a low level in a cultivation vessel during the culture feeding in aerobic fed-batch, continuous or cell-recycling continuous cultures. This is accomplished by monitoring the increase in pH or dissolved oxygen content in the culture medium and adding the feed solution intermittently into a cultivation vessel at a calculated feed rate using a feed control device controlled by a computer.The present invention further relates to a process for producing L-lysine by fermentation having the advantages over the prior methods, those being improved productivity, higher concentrations of accumulated product, and increased yields of L-lysine.Type: GrantFiled: November 17, 1998Date of Patent: February 15, 2000Assignee: Ajinomoto Co., Inc.Inventors: Takashi Nakamura, Tatsuya Nakayama, Yosuke Koyama, Keishi Shimazaki, Harufumi Miwa, Minoru Tsuruta, Koji Tamura, Osamu Tosaka
-
Patent number: 6024964Abstract: According to certain embodiments, the invention relates to a method of producing antibodies employing an immunoconjugate produced by conjugating at least one membrane-anchoring compound with at least one partial sequence of a viral, bacterial, or protoral protein. The immunoconjugate has the advantage that it can be stored for a very long time even without cooling. According to certain embodiments, the invention relates to an immunoconjugate for the specific induction of cytotoxic T-lymphocytes which comprises a conjugate from at least one membrane anchor compound and a protein, containing at least one killer T-cell epitope, of a virus, a bacterium, a parasite or a tumor antigen, or at least one partial sequence containing at least one killer T-cell epitope of a viral, bacterial or parasite protein or of a tumor antigen.Type: GrantFiled: June 6, 1995Date of Patent: February 15, 2000Assignee: Hoechst AktiengesellschaftInventors: Gunther Jung, Karl-Heinz Wiesmuller, Jorg Metzger, Hans-Jorg Buhring, Gerhard Becker, Wolfgang Bessler
-
Patent number: 6024963Abstract: An enhanced immune response to antigens, particularly normally weakly-immunogenic viral antigens, such as the HA antigen from influenza virus, is achieved by coadministering the antigen in two different physio-chemical forms, particularly to enable presentation of antigen both by B cells and accessory cells.Type: GrantFiled: November 17, 1998Date of Patent: February 15, 2000Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Karen Biscardi, Laura Ferguson, Lorne Erdile
-
Patent number: 6017967Abstract: The invention relates to a metal sulfide dispersion used for electroplating nonconductors such as substrates used for the formation of a printed circuit board. A printed circuit board made using the dispersion could have metallized through-holes comprising electrodeposited copper on the walls of the holes with an adsorbed layer of metal sulfide particles between the circuit board base material and the copper on the walls of the through-holes. The metal sulfide is characterized by spherical particles having a mean diameter of less than 100 nanometers and a particle size distribution where less than 10 percent of the particles within the dispersion have a diameter twice that of the mean diameter of all particles within the dispersion.Type: GrantFiled: April 1, 1996Date of Patent: January 25, 2000Assignee: Shipley Company, L.L.C.Inventors: Egon Matijevic, Matthias Schultz, Wade Sonnenberg, John J. Bladon, Patrick J. Houle, Thong B. Luong
-
Patent number: 6013532Abstract: Microbiological entities, such as cells or microbes, are immobilized in a single-file linear array for optical analysis. Colloidal magnetic particles having a binding agent, such as ligand for attachment with a corresponding receptor, are bound to the entities suspended in a fluid medium. The fluid medium is placed into a vessel having a ferromagnetic capture structure including an elongated linear collection surface with a diameter less than that of the microbiological species of interest. The vessel is placed into a magnetic field for inducing a magnetic gradient in a region along the collection surface of the ferromagnetic capture structure. The magnetically-labeled entities are attracted toward the collection surface and immobilized thereon in a linear array. Microscopic optical and fluorescence observations, and sequential chemical reactions and mechanical manipulations may be performed on the line of immobilized entities.Type: GrantFiled: June 19, 1997Date of Patent: January 11, 2000Assignee: Immunivest CorporationInventors: Paul A. Liberti, Yuzhou Wang
-
Patent number: 6004798Abstract: A retroviral vector particle having a modified retroviral envelope polypeptide. The retroviral envelope polypeptide includes the hypervariable polyproline region, or hinge region, and the hypervariable polyproline region, or hinge region is modified to include a targeting polypeptide including a binding region which binds to a ligand. Such a retroviral vector may be "targeted" to various cells for delivery of genetic material to such cells.Type: GrantFiled: May 14, 1997Date of Patent: December 21, 1999Assignee: University of Southern CaliforniaInventors: W. French Anderson, Bonnie Weimin Wu
-
Patent number: 5994077Abstract: Regulatory elements (e.g. promoters) activated by a stimulus are isolated by a FACS-based method. Preferably, a library of random fragments representative of a target (e.g. bacterial) genome are cloned in front of a promoterless gfp (green fluorescent protein) sequence in a plasmid, and inserted into target cells. The resulting target cell mixture is sorted according to GFP levels in the presence and the absence of the stimulus. Suitable stimuli include compounds of interest (e.g. drugs), environmental factors (e.g. extracellular acidity), and complex stimuli such as in vivo environments of hosts infected by the target cells. The method allows identifying pathogen genes which are selectively expressed during infection.Type: GrantFiled: September 10, 1997Date of Patent: November 30, 1999Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Raphael H. Valdivia, Brendan P. Cormack, Stanley Falkow
-
Patent number: 5993823Abstract: Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide fragment having approximately between 10 and 40 amino acids and comprising at least one antigenic determinant and also comprising one or more chains derived from fatty acids and one or more modified steroid groups useful for immunizing a human or animal body against pathogenic agents such as viruses or parasites which fragment is preferably a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignee: Institut Pasteur de LilleInventors: Christophe Boutillon, Frederic Martinon, Christian Sergheraert, Remy Magne, Helene Gras-Masse, Elisabeth Gomard, Andre Tartar, Jean-Paul Levy
-
Patent number: 5993819Abstract: The present invention relates to immunogenic preparations of peptides comprising amino acid sequences corresponding to antigenic determinants of the envelope glycoprotein of HIV, covalently coupled, directly or through a spacer molecule, to carrier molecules suitable for vaccination of mammals.Type: GrantFiled: October 20, 1995Date of Patent: November 30, 1999Assignee: Duke UniversityInventors: Barton F. Haynes, Thomas J. Palker
-
Patent number: 5993812Abstract: Therapeutic and prophylactic methods using Rh antibodies for delaying the progression of infection with the Human Immunodeficiency Virus (HIV) in a subject who is exposed to HIV, or infected by HIV.Type: GrantFiled: April 7, 1997Date of Patent: November 30, 1999Assignee: Cangene CorporationInventors: Christos M. Tsoukas, Barry Michael Woloski
-
Patent number: 5989828Abstract: A novel surface exposed protein of Haemophilus influenzae or related Haemophilus species is described. The protein named protein D is an Ig receptor for human IgD and has an apparent molecular weight of 42,000. Protein D can be detected in all of 116 encapsulated and non-encapsulated isolates of H. influenzae studied. The protein from all strains shows in addition to the same apparent molecular weight immunogenic similarities since protein D from all strains interacts with three different mouse monoclonal antibodies and monoclonal human IgD. A method for purification of protein D is described. Cloning of the protein D gene from H. influenzae in E. coli is described as well as the nucleotide sequence and the deduced amino acid sequence.Type: GrantFiled: November 12, 1996Date of Patent: November 23, 1999Inventor: Arne Forsgren
-
Patent number: 5989378Abstract: An ink jet recording material is constituted by a support and a recording layer on the support, in which a plurality of recording layer may be provided. At least one recording layer contains colloidal particles and a water-soluble resin. In order to produce the ink jet recording material, a sticking or adhesive interlayer is provided on a support, and a recording layer including at least one layer is superposed on the interlayer. At least one of the at least one layer of the recording layer contains colloidal particles and a water-soluble resin, and the recording layer is coated and formed on a forming material. Then, the forming material is peeled from said recording layer.Type: GrantFiled: August 21, 1996Date of Patent: November 23, 1999Assignee: New Oji Paper Co., Ltd.Inventors: Bo Liu, Hiroyuki Nemoto, Hideo Ikezawa
-
Patent number: 5981296Abstract: Stabilized particle reagents suitable for use in turbidimetric immunoassays are disclosed. The stabilized particle reagents contain functionalized polymer particles in which the surface of the particle has been modified with a molecular surface modifier having the structure:R(OCH.sub.2 CH.sub.2).sub.n NH.sub.2in which: R is --H, --CH.sub.3 or --CH.sub.2 CH.sub.3, and n is an integer between 2 and 10, inclusive. The stabilized particle reagents are resistant to premature or spontaneous aggregation during preparation or storage.Type: GrantFiled: February 18, 1997Date of Patent: November 9, 1999Assignee: Dade Behring Inc.Inventor: Richard Wayne Stout
-
Patent number: 5976541Abstract: Peptides having high activity in the eliciting of a cytotoxic T lymphocyte response to the HIV-1 envelope glycoprotein gpl60 are described. The activation of 12-15 residue peptides by proteolytic degradation to shorter peptides is shown as are general techniques for characterizing such activation processes.Type: GrantFiled: March 6, 1992Date of Patent: November 2, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jay A. Berzofsky, Toshiyuki Taskeshita, Mutsunori Shirai, C. David Pendleton, Steven Kozlowski, David H. Margulies
-
Patent number: 5972633Abstract: The present invention relates to antibodies against heart muscle actin, processes for the production of such antibodies and their use.Type: GrantFiled: January 14, 1998Date of Patent: October 26, 1999Assignee: Progen Biotechnik GmbHInventors: Werner Wilhelm Franke, Sabine Stumpp, Sabine Stehr